Literature DB >> 9632590

Induction of protective immune responses by immunization with linear multiepitope peptides based on conserved sequences from Plasmodium falciparum antigens.

A Bharadwaj1, P Sharma, S K Joshi, B Singh, V S Chauhan.   

Abstract

A cysteine-containing peptide motif, EWSPCSVTCG, is found highly conserved in the circumsporozoite protein (CSP) and the thrombospondin-related anonymous protein (TRAP) of all the Plasmodium species analyzed so far and has been shown to be crucially involved in the sporozoite invasion of hepatocytes. We have recently shown that peptide sequences containing this motif, and also the antibodies raised against the motif, inhibit the merozoite invasion of erythrocytes. However, during natural infection, and upon immunization with recombinant CSP, this motif represents a cryptic epitope. Here we present the results of immunization studies with two linear multiepitopic constructs, a 60-residue (P60) and a 32-residue (P32) peptide, containing the conserved motif sequence. Both the peptides per se generated high levels of specific antibodies in BALB/c mice. P32 was found to be genetically restricted to H-2(d) and H-2(b) haplotypes of mice, whereas P60 was found to be immunogenic in five different strains of mice. The antibody response was predominantly targeted to the otherwise cryptic, conserved motif sequence in P60. Anti-P60 antibodies specifically stained the asexual blood stages of Plasmodium falciparum and Plasmodium yoelii in an immunofluorescence assay, recognized a 60- to 65-kDa parasite protein in an immunoblot assay, and blocked P. falciparum merozoite invasion of erythrocytes in a dose-dependent manner. Immunization with P60 also induced significant levels of the cytokines interleukin-2 (IL-2), IL-4, and gamma interferon in BALB/c mice. Moreover, >60% of mice immunized with P60 survived a heterologous challenge infection with a lethal strain of P. yoelii. These results indicate that appropriate medium-sized synthetic peptides might prove useful in generating specific immune responses to an otherwise cryptic but critical and putatively protective epitope in an antigen and could form part of a multicomponent malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632590      PMCID: PMC108337     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

1.  Target antigens for asexual malaria vaccine development.

Authors:  R J Howard; B L Pasloske
Journal:  Parasitol Today       Date:  1993-10

2.  Polarity of immunogens: implications for vaccine design.

Authors:  J Golvano; J J Lasarte; P Sarobe; A Gullón; J Prieto; F Borrás-Cuesta
Journal:  Eur J Immunol       Date:  1990-10       Impact factor: 5.532

3.  Antibodies to a conserved-motif peptide sequence of the Plasmodium falciparum thrombospondin-related anonymous protein and circumsporozoite protein recognize a 78-kilodalton protein in the asexual blood stages of the parasite and inhibit merozoite invasion in vitro.

Authors:  P Sharma; A Bharadwaj; V K Bhasin; V N Sailaja; V S Chauhan
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule.

Authors:  M F Good; D Pombo; I A Quakyi; E M Riley; R A Houghten; A Menon; D W Alling; J A Berzofsky; L H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

5.  Theoretically determined three-dimensional structure for the repeating tetrapeptide unit of the circumsporozoite coat protein of the malaria parasite Plasmodium falciparum.

Authors:  B R Brooks; R W Pastor; F W Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 6.  Acquired immunity and vaccination in malaria.

Authors:  S Cohen; G A Butcher; G H Mitchell; J A Deans; J Langhorne
Journal:  Am J Trop Med Hyg       Date:  1977-11       Impact factor: 2.345

7.  Co-dominant and reciprocal T-helper cell activity of epitopic sequences and formation of junctional B-cell determinants in synthetic T:B chimeric immunogens.

Authors:  P Sharma; A Kumar; S Batni; V S Chauhan
Journal:  Vaccine       Date:  1993-10       Impact factor: 3.641

Review 8.  T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages.

Authors:  E H Nardin; R S Nussenzweig
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

9.  A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.

Authors:  D C Kaslow; I A Quakyi; C Syin; M G Raum; D B Keister; J E Coligan; T F McCutchan; L H Miller
Journal:  Nature       Date:  1988-05-05       Impact factor: 49.962

10.  Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum.

Authors:  J B Dame; J L Williams; T F McCutchan; J L Weber; R A Wirtz; W T Hockmeyer; W L Maloy; J D Haynes; I Schneider; D Roberts
Journal:  Science       Date:  1984-08-10       Impact factor: 47.728

View more
  8 in total

Review 1.  Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design.

Authors:  Javier E Garcia; Alvaro Puentes; Manuel E Patarroyo
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

2.  Analysis of immune responses against T- and B-cell epitopes from Plasmodium falciparum liver-stage antigen 1 in rodent malaria models and malaria-exposed human subjects in India.

Authors:  S K Joshi; A Bharadwaj; S Chatterjee; V S Chauhan
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

3.  Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya.

Authors:  Chandy C John; Joseph S Zickafoose; P Odada Sumba; Christopher L King; James W Kazura
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

4.  Expression, purification, and characterization of the immunological response to a 40-kilodalton Plasmodium vivax tryptophan-rich antigen.

Authors:  Asim A Siddiqui; Hema Bora; Neeru Singh; Aditya P Dash; Yagya D Sharma
Journal:  Infect Immun       Date:  2008-03-24       Impact factor: 3.441

5.  Antibody response of healthy adults to recombinant thrombospondin-related adhesive protein of cryptosporidium 1 after experimental exposure to cryptosporidium oocysts.

Authors:  Pablo C Okhuysen; G Aaron Rogers; Andrea Crisanti; Furio Spano; David B Huang; Cynthia L Chappell; Saul Tzipori
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

6.  Plasmodium vivax Pv12 B-cell epitopes and HLA-DRβ1*-dependent T-cell epitopes in vitro antigenicity.

Authors:  Yoelis Yepes-Pérez; Carolina López; Carlos Fernando Suárez; Manuel Alfonso Patarroyo
Journal:  PLoS One       Date:  2018-09-10       Impact factor: 3.240

7.  Novel antibody against a glutamic acid-rich human fibrinogen-like protein 2-derived peptide near Ser91 inhibits hfgl2 prothrombinase activity.

Authors:  Wen-Zhu Li; Jue Wang; Rui Long; Guan-Hua Su; Dinesh-Kumar Bukhory; Jing Dai; Nan Jin; Shi-Yuan Huang; Peng Jia; Ting Li; Chen Fan; Kun Liu; Zhaohui Wang
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

Review 8.  The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design.

Authors:  Catherine J Mitran; Stephanie K Yanow
Journal:  Front Immunol       Date:  2020-02-27       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.